Eric Souied Joins SeaBeLife - Scorecard - MDSpire

Eric Souied Joins SeaBeLife

  • March 9, 2026

  • 2 min

Share

Clinical Scorecard: Eric Souied Joins SeaBeLife

At a Glance

CategoryDetail
ConditionAge-Related Macular Degeneration (AMD)
Key MechanismsInhibition of necroptosis and ferroptosis
Target PopulationIndividuals with geographic atrophy (GA) associated with AMD
Care SettingOphthalmology clinics and research settings

Key Highlights

  • Professor Eric Souied appointed to SeaBeLife's scientific committee
  • Focus on dual-pathway strategy targeting retinal degeneration
  • SBL03 shows preclinical efficacy in geographic atrophy
  • GA affects an estimated eight million people worldwide
  • Limited treatment options available in Europe

Guideline-Based Recommendations

Diagnosis

  • Identify genetic polymorphisms associated with AMD
  • Assess for geographic atrophy in early-stage disease

Management

  • Implement disease-modifying approaches targeting necroptosis and ferroptosis

Monitoring & Follow-up

  • Regular assessments of retinal health and progression of GA

Risks

  • Progressive loss of retinal pigment epithelium and photoreceptors

Patient & Prescribing Data

Patients with geographic atrophy due to AMD

Focus on addressing underlying drivers of degeneration

Clinical Best Practices

  • Utilize a mechanistic approach to understand retinal degeneration
  • Incorporate lipid metabolism and oxidative stress in treatment strategies
  • Engage in regulatory strategy and trial design for new therapies

References

Original Source(s)

Related Content